发明名称 |
Protein therapy for treatment of retinal diseases |
摘要 |
The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein. |
申请公布号 |
US9090704(B2) |
申请公布日期 |
2015.07.28 |
申请号 |
US201414284911 |
申请日期 |
2014.05.22 |
申请人 |
Scott & White Healthcare;The Texas A&M University System |
发明人 |
Rosa Robert;Roddy Gavin W.;Prockop Darwin J. |
分类号 |
A61K38/17;A61K38/16;C07K14/575;A61K38/22;A61K35/28 |
主分类号 |
A61K38/17 |
代理机构 |
Hodgson Russ LLP |
代理人 |
Hodgson Russ LLP |
主权项 |
1. A method for inhibiting apoptosis of retinal pigment epithelium (RPE) in a subject in need thereof, comprising administering to the eye of the subject a pharmaceutically effective amount of a composition that comprises a polypeptide comprising a domain comprising a stanniocalcin family member polypeptide, wherein the stanniocalcin family member polypeptide is a STC-1 polypeptide that has at least 95% sequence identity to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, or SEQ ID NO:11. |
地址 |
Temple TX US |